PMC:4996393 / 26181-27361 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4996393","sourcedb":"PMC","sourceid":"4996393","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4996393","text":"4. Conclusions \nRPPA is a high-throughput method due to the simultaneous analysis of different biomarkers in one sample. One great advantage is that RPPA works with very small amounts of proteins. For this reason, even biopsies are sufficient for RPPA analysis. The implementation of RPPA into clinical practice would help to provide optimal tumor analysis prior and during treatment, enabling to apply the best (i.e., individualized) therapy for each patient, even in the neoadjuvant setting. Due to automated systems that print the proteins of tumor samples on nitrocellulose-coated glass slides, RPPA analysis is simple and rapid. In our opinion, even if the method is limited to high-specific validated antibodies (like for all antibody-based methods), we think that patients, e.g., tumor patients, would benefit from robust tumor marker analysis by RPPA in clinical routine. However, inter-assay reproducibility has to be ensured and clinically validated cut-off levels need to be determined for each tumor marker. Therefore, clinical trials and RPPA-based treatment decisions performed with input material of the highest possible quality will be necessary in the next years.","divisions":[{"label":"Title","span":{"begin":0,"end":15}}],"tracks":[]}